Marshall Fordyce, Director, President, and CEO, on June 23, 2026, sold 18,500 shares in Vera Therapeutics (VERA) for $701,769. Following the Form 4 filing with the SEC, Fordyce has control over a total of 420,274 Class A common shares of the company, with 198,244 shares held directly and 222,030 controlled indirectly.
SEC Filing:
Musa Tariq, Director, on June 22, 2026, sold 1,951 shares in Guardant Health (GH) for $255,893. Following the Form 4 filing with the SEC, Tariq has control over a total of 11,048 common shares of the company, with 11,048 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1576280/000196828126000018/xslF345X05/wk-form4_1782250150.xml
John D Quisel, Director, Chief Executive Officer, on June 18, 2026, sold 34,000 shares in Disc Medicine (IRON) for $2,387,296. Following the Form 4 filing with the SEC, Quisel has control over a total of 226,064 common shares of the company, with 226,064 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1816736/000119312526279779/xslF345X05/ownership.xml
Bruce C. Taylor, Director, on June 22, 2026, executed a purchase for 100,000 shares in Mission Produce (AVO) for $1,128,269. Following the Form 4 filing with the SEC, Taylor has control over a total of 6,791,540 common shares of the company, with 755,505 shares held directly and 6,036,035 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1802974/000145935026000006/xslF345X05/wk-form4_1782248789.xml